Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180 [Phase 1]

View source ↗

Summary

Phase 1 trial update for APL180 reporting safety, tolerability, and pharmacokinetic/pharmacodynamic profiles in subjects with coronary heart disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• APL180

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Coronary Heart Disease | Phase 1 | Status: COMPLETED